A characteristic feature of host responses to helminth infections is the development of
profound systemic and tissue-localised Type 2 immune responses that play critical roles in …

Abstract Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory
responses following tissue damage or infection and is a promising target for treatment of …

Introduction In response to injury, epithelial cells release alarmins including thymic stromal
lymphopoietin (TSLP), high mobility group-box-1 (HMGB1), interleukin (IL)-33 and− 25 that …

BACKGROUND IL-33, found in high levels in participants with allergic disorders, is thought
to mediate allergic reactions. Etokimab, an anti–IL-33 biologic, has previously demonstrated …

Patients who are prone to exacerbations of asthma experience significant costs in terms of
missed work and school, acute care visits, and hospitalizations. Exacerbations are largely …

Background Respiratory virus infections are main triggers of asthma exacerbations.
Tezepelumab, an anti‐TSLP mAb, reduces exacerbations in patients with asthma, but the …

Background Asthma is a complex disease with multiple phenotypes that may differ in
disease pathobiology and treatment response. IL33 single nucleotide polymorphisms …

Recent studies have shown that the estrogen receptor α (ERα), but not ERβ, is involved in
the proinflammatory and propruritic responses in cutaneous allergy. In addition, results from …

Background Interleukin-33 is recently identified as a brain injury biomarker. We determined
whether serum interlerukin-33 concentrations are associated with inflammation, severity and …

Background and aims The chemoattractant receptor-homologous molecule expressed on T
helper type 2 cells (CRTH2) antagonist timapiprant improved lung function and asthma …